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Human promyelocytic cell lines can be induced to differentiate in vitro along 
the myeloid or the monocytic pathway depending on the chemical or biological 
inducers used (1-4).  Induction of promyelocytic ceil lines along the monocytic 
pathway can be readily demonstrated by culturing the cells in the presence of 
medium  conditioned  by  iectin-stimulated  leukocytes  (5-9).  Most  cells  from 
human promyelocytic cell lines, such as HL-60 or ML3, cultured in the presence 
of conditioned medium from phytohemagglutinin-stimulated lymphocytes (PHA- 
CM), ~ express monocyte-specific antigens,  including HLA-DR, and surface re- 
ceptors and enzymes typical of monocytes (6, 9). The cells acquire morphological 
characteristics of differentiated monocyte-macrophages and the ability to mediate 
active phagocytosis and antibody-dependent cytotoxicity (Ab-CMC) (9), but lose 
the ability to proliferate in culture (7, 9). It has also been shown that PHA-CM 
can induce at least partial monocytic differentiation in cells freshly obtained from 
patients with acute myelogenous leukemia (AML) (10). 
Lectin-stimulated lymphocytes secrete a  variety of soluble factors  including 
colony-stimulating factors (CSF) (11), interferons (IFN) (12,  13), and the T  cell 
growth factor, interleukin 2 (IL-2) (14). The ability of all I FN types to modulate 
cellular functions, in addition to exerting antiviral activity, has been described, 
and most of these anticeilular effects are inhibitory, with marked suppression of 
cellular DNA and protein synthesis. However, IFN can also stimulate the func- 
tions of the effector cells of nonadaptive immunity, natural killer (NK) cells and 
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monocyte-macrophages (15,  16),  efficiently enhancing nonspecific effector cell 
activity (17).  Human  IFNa  induces an arrest  in  granulopoietic  maturation of 
colonies grown  in vitro at the level of small clusters (18),  and purified mouse 
IFN enhances differentiation of M 1 mouse myeloid leukemic cells to monocyte- 
macrophages induced by macrophage CM or polyinosinic acid (19). IFNa, IFN3, 
and (2'5')oligo-isoadenylate can induce the human macrophage cell line U937, 
but not the more  immature  HL-60 cell  line,  to mediate Ab-CMC (20).  IFNy 
induces or enhances the expression of Ia antigens on a variety of cell types (21- 
25) and the expression of the receptor for the Fc fragment of monomeric IgG 
on myelomonocytic cells (26).  We recently observed that human IFN'), can not 
only induce HLA-DR expression on promyelocytic cell lines, but, like PHA-CM, 
can  also  induce  expression  of the  surface  antigens,  enzymes,  and  functional 
activities characteristic of cells differentiating along the monocytic pathway.  2 
In this report, we show that PHA-CM can induce terminal monocytic differ- 
entiation in human immature myeloid cells obtained from normal bone marrow 
or from peripheral blood of patients with chronic myelogenous leukemias (CM L) 
or other myeloproliferative disorders. We also identify the active component of 
PHA-CM  that effects this induction in  normal myeloid cells and in cells from 
acute and chronic myelogenous leukemia patients as IFN'),. 
Materials and Methods 
Patients.  Hematologically  normal bone marrow specimens were obtained for diagnostic 
purposes from donors at the Thomas Jefferson University Hospital, Philadelphia or from 
normal donors at the Children's Hospital of Philadelphia. Peripheral blood was obtained 
from eight patients with CML and one with myeloid metaplasia at the Hospital of  Jefferson 
University. Seven out of eight CML patients were  Philadelphia chromosome positive. 
Four of these patients were untreated when tested for the first time, and the others were 
treated with Myleran (Burroughs Wellcome Co., Research Triangle Park, NC),  hydrox- 
yurea, or both. Cells from adult patients with AML were typed according to the French- 
American-British classification  (FAB) at the Hospital of the University of Pennsylvania, 
Philadelphia, and the identification was confirmed by one of us (J. H.) through analysis 
of the cells with a large panel of anti-human leukocyte monoclonal antibodies by indirect 
immunofluorescence (flow cytofluorometry). 
Monoclonal Antibodies.  Most mouse anti-human leukocyte monoclonal antibodies used 
in this study were produced and characterized in our laboratory. The IgG2b pan-T cell 
antibody B36.1 (27) detects the 69,000-71,000 mol wt protein complex and has the same 
specificity  as antibodies OKT1  and L17FI2 (anti-Leu-1) (28,  29).  Two non-cross-com- 
peting IgG2a antibodies, B67.1  and B67.6, react with the 45 K mol wt protein of T cells, 
presumably identified as the receptor for sheep erythrocytes (E) (27).  Antibody B73.1 
(27, 30) (IgG1) reacts with a 65-72 K mol wt protein complex present on large granular 
lymphocytes (LGL) and on neutrophilic polymorphonuclear ieukocytes (PMN)  that is 
probably the receptor for the Fc fragment of aggregated immunoglobulin (FcR)  (31). 
The IgM antibodies B44.1  (32), B52.1  (9), and B77.1  specifically react with all peripheral 
blood monocytes and all a-naphthylacetate esterase (a-NAE)-positive  cells in the bone 
marrow.  Antibodies  B44.1  and  B52.1  cross-compete  with  each  other  and  with  the 
antimonocyte antibody Mo2 (33) for binding sites on monocytes. Antibody B77.1  does 
not cross-compete with any of the other antibodies and is presumably directed against a 
separate antigenic determinant expressed on monocytes (unpublished results).  B40.8 and 
B37.2 (32) are two cross-reacting IgM antibodies of identical specificity: they react with 
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all  normal myeioid cells and with a  proportion of myeloid precursor ceils  in the bone 
marrow. The subset of cells defined by B40.8 and B37.2 and the subset defined by B44.1, 
B52.1, and B77.1 in normal peripheral blood and bone marrow leukocytes are nonover- 
lapping  (32).  The  IgM  antibody  B13.4  (32,  34)  reacts  with  both  mature  PMN  and 
monocytes and, within cells of the myeloid lineage, reacts only with metamyelocytes or 
more mature cells.  The IgG2a antibody B33.1  (27,  32) reacts with a  nonpolymorphic 
determinant of the HLA-DR antigen (human Ia-like antigens). The F(ab')~  fragment of 
B33.1, prepared by pepsin digestion, was used throughout this study. The IgG2a antibody 
DI-12 (35), kindly provided by Dr. R. Accolla, Ludwig Institute for Cancer Research, 
Lausanne, Switzerland, is directed to one product of the DR locus in the HLA complex. 
Monoclonal antibodies Q2/70, Q2/80, Q5/6, and Q5/13 are directed against different 
subpopulations of human Ia molecules (36) and were kindly provided by Dr. S. Ferrone, 
Columbia University, New York. 
Isolation of Immature Myeloid Cells.  Peripheral blood and bone marrow samples were 
anticoagulated with heparin and layered on a single-step Ficoll/Hypaque (F/H) discontin- 
uous gradient (1.077 _+ 0.01  g/ml) to remove mature erythroid and myeloid cells. The 
mononuclear cells, obtained from the interface of the gradient, were depleted of mature 
adherent monocytic cells by two cycles of adherence to plastic surfaces (45 min at 37°C). 
Nonadherent mononuclear cells were depleted of contaminating monocytes, T  iympho- 
cytes, and NK cells using indirect rosetting (as described later) and F/H gradient after 
sensitization of the  cell  suspension  with  a  mixture of the  anti-T  B36.1,  anti-sheep  E 
receptor B67.1 and B67.6, anti-NK/K cell B73.I, and antimonocyte B44.1  and B52.1. 
The negative cell population, highly enriched for myeloid cells, was in some experiments 
purified further. Indirect rosetting with antibody B13.4 and F/H gradient were used to 
separate the total myeloid cell population from CML patients into a more mature B 13.4+ 
population, composed mostly of metamyelocytes and banded cells, and a more immature 
B13.4- population, composed of myeiocytes and a minor component of more immature 
or mature cells.  Peripheral blood mononuclear cells from patients with acute leukemia 
were separated by F/H gradient centrifugation and maintained frozen in liquid nitrogen 
until induced in culture. 
Conditioned Medium.  Human peripheral blood mononuclear cells were irradiated (20 
Gy) and  incubated  (106/ml)  in  RPMI  1640  medium  supplemented  with  1%  PHA-M 
(Wellcome Research Laboratories, Beckenham, Kent, England) and 1% fetal bovine serum 
(FBS) (Gibco Laboratories, Grand Island, NY) for 72 h at 37°C in 5% CO~ in air. Cell- 
free supernatant was collected and used as a crude PHA-CM preparation. 
IFN Preparation.  Purified  human  IFN3,  (106  U/mg  protein  on  HEp-2  cells)  was 
obtained from Interferon Sciences, Inc., New Brunswick, NJ. Human recombinant IFN3, 
(rIFN~,)  from E. coli was kindly supplied by Dr. C. G. Sevastopoulos, Genentech, Inc., 
San Francisco, CA and it has a titer of 5 X 107 antiviral U/mg on HeLa cells. Because of 
the variability of the titer of IFN3, on different cell lines and the lack of an international 
standard for I FN3,, concentrations of rIFN3, are expressed in ng/ml rather than antiviral 
units. The concentration used in most experiments, 100 ng/ml, corresponds to ~500 U/ 
ml on HeLa cells. No significant CSF activity was demonstrable in the rIFN3, preparation 
using either normal  bone marrow cells or peripheral blood cells  from CML patients. 
Partially purified IFNa (Leucoferon; 106 antiviral U/mg) was obtained from Biotechnol- 
ogies Inc., Hartford, CT. Recombinant types A and D IFNa from Escherichia coli (rIFNA 
and rIFND) were kindly supplied by Hoffmann-LaRoche, Inc., Nutley, NJ. Crude IFN/3 
was obtained from Lee Biomolecular Research Lab., Inc., San Diego, CA, and purified 
IFN/3 was kindly supplied by Dr. A. Billiau,  (preparation No.  16287; Leuven, Belgium). 
Rabbit antiserum against human  IFN3,  (104 neutralization U/ml) and sheep antiserum 
against human IFNa (105 neutralization U/ml) were obtained from Interferon Sciences, 
Inc. Using a colony assay in methyl cellulose with peripheral blood CML target cells, no 
inhibition of the CSF activity contained in PHA-CM or in GCT medium (Gibco Labora- 
tories) was observed after treatment with anti IFN7 serum. 
Culture of Myeloid Cells.  Enriched preparations of myeloid cells  from patients were 
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supplemented with 10% FBS at 37°C in 5% CO~ in air. All dilutions of PHA-CM or IFN 
were prepared  in  this  medium.  The absolute number of cells recovered after 5  d  of 
culture was approximately the original input under any of the experimental conditions. 
Viability,  as  evaluated  by dye  exclusion  test,  was  between  75  and  95%  and  was  not 
significantly different among samples. To avoid nonspecific binding and autofluorescence 
in immunofluorescence assays, the cells recovered after 5 d of culture were depleted of 
dead cells by centrifugation over a single-step F]H gradient. 
Cell Morphology.  Cell morphology was examined on cytocentrifuge preparations (Cy- 
tospin centrifuge; Shandon Southern Instrument Inc., Sewickley, PA), stained by the May- 
Grunwald-Giemsa method. Staining for a-NAE was carried out according to Platt (37). 
Electron Microscopy.  Cells were fixed in 3% glutaraldehyde (vol/vol) (Fisher Scientific 
Co.,  Pittsburgh,  PA) in  PIPES buffer, pH 7.2  (Sigma Chemical Co., St.  Louis, MO), at 
4°C  for 30-60  min, and postfixated in  1%  OsO4 (Electron  Microscopy (EM) Sciences, 
Fort Washington,  PA) in  PIPES buffer for  1 h  at 20°C.  Specimens were stained  with 
uranyl acetate (1% aqueous solution; EM  Sciences) for  18 h  at 60°C,  dehydrated  with 
alcohol, and embedded in Epon (EM Sciences). Sections 50-80 nm thick were cut with a 
Porter-Blum MT2 ultramicrotome (DuPont Instruments-Sorvall Biomedical Div., DuPont 
Co., Wilmington, DE) with a diamond knife and were stained with lead citrate. Sections 
were examined in a Hitachi HU 11-E electron microscope. 
Detection of FcR.  Ox  erythrocytes (E)  sensitized  with  rabbit  IgG anti-ox  E  (EA7S) 
(Cappel Laboratories, Cochranville, PA) were used as the indicator system for FcR. Cells 
and E were mixed (1:50) and incubated as pellets for 20 min at 4°C. The proportion of 
cells forming rosettes with sensitized E was determined by scoring at least 200 cells; only 
cells with more than five E bound were considered as positive. 
Indirect Immunofluorescence Studies.  Cells were sequentially incubated with appropriate 
dilutions of the different monoclonai antibodies and fluorescein isothiocyanate (FITC)- 
labeled goat F(ab')~ anti-mouse Ig antibody for 30 rain at 0°C as described (34). The cells 
were then  washed at 4°C  with  phosphate-buffered saline (PBS)  containing  5%  normal 
human serum. When the populations separated by indirect rosetting were assayed, they 
were first incubated with biotin-labeled antibodies (38), and then with FITC-avidin (Vector 
Laboratories, Inc., Burlingame, CA). The proportion of cells reactive with the different 
antibodies was scored on an Ortho Cytofluorograf 50H (Ortho Diagnostic Systems, Inc., 
Westwood, MA) connected to a Data General MP/200 microprocessor. The fluorescence 
signals were assigned into 200 channels by a pulse height analyzer, using a  linear scale. 
The threshold fluorescence channel was used at which 99% of the cell population treated 
with control supernatant from the parental myeloma and FITCoanti-mouse Ig antibodies 
or  FITC-avidin  were  negative.  Fluorescence  intensity,  within  each  experiment,  was 
evaluated by determining the mean fluorescence channel of positive cells. 
Separation of Cells Reactive with Monoclonal Antibodies by Indirect Rosetting.  Cells sensitized 
with the monoclonal antibodies were incubated for 1 h at 4 °C as pellets with CrCl~-treated 
sheep E coated with affinity-purified goat F(ab')2 anti-mouse Ig as described (34). Under 
these conditions, no rosette formation was ever observed on control cells not sensitized 
with antibody.  Rosetting and nonrosetting cells were then separated on a one-step F/H 
gradient. Contaminating E in the positive fraction were lysed by treatment with hypotonic 
medium. 
Cell-mediated Cytotoxicity Assay.  Lytic activity was tested in a  3-h "~Cr-release assay by 
incubating  various  numbers  of effectors in  microtiter plates at  37°C  with  a  constant 
number (104) of ~Cr-labeled P815Y target cells sensitized with a  1/1,500  dilution of a 
rabbit anti-P815Y serum prepared in our laboratory. Supernatants were harvested and 
percent specific cytotoxicity was calculated as previously reported (39). One iytic unit 45% 
(LU) is defined as the number of effector cells required to mediate 45%  specific ~Cr- 
release from  104 target cells in the  3-h assay. LU per  107 cells were calculated using a 
modified Van Krogh equation as described (40). 
['~H]Thymidine Incorporation.  Myeloid cells from CML patients were cultured in flat- 
bottomed plates with or without 50% PHA-CM or 100 n~/ml rlFN% At different times, 
aliquots from the same sample were pulsed for 1 h with [" H]thymidine ([3H]TdR) (2 #Ci/ 2062  IMMUNE  INTERFERON-INDUCED MONOCYTIC DIFFERENTIATION 
well, 2 Ci/mmol specific activity; New England  Nuclear,  Boston,  MA). Cells were then 
washed and cytocentrifuge smears were prepared, fixed in absolute methanol for 30 rain, 
and covered with NTB-2 emulsion (Eastman Kodak Company,  Rochester, NY) for a 2-d 
exposure. After developing,  cells were stained with hematoxylin.  The proportion of cells 
incorporating [~H]TdR was scored by counting at least 300 cells. 
Results 
Effect  of PHA-CM and  Recombinant  IFN3" (rlFNy)  on  Cultures of Normal  Bone 
Marrow.  Normal bone marrow cells, prepared as described, were maintained in 
liquid cultures for 5  d  in culture medium supplemented or not with  PHA-CM 
(50%  vol/vol) or rlFN'r  (50 ng/ml).  The cells were then washed through  FBS 
and tested for expression of surface antigens and FcR by indirect immunofluo- 
rescence (flow cytofluorometry) and by rosetting with EA7S, respectively. Table 
I shows results obtained with  11 different bone marrow specimens. Myeloid cells 
predominate in the cell preparations, as indicated by the large proportion of cells 
reactive with antibody B40.8.  However, expression of the  myeloid antigen,  as 
detected by this antibody, did not change significantly as a result of PHA-CM or 
IFN~  treatment.  In  all  cases,  treatment  with  PHA-CM  or rlFN~,  consistently 
determined a  marked increase in the percentage of HLA-DR  ÷ cells as detected 
by antibody B33.1. On day 0, the cell preparations had been depleted of adherent 
and of almost all  B52.1 + cells. After 5 d  culture in the absence of inducers,  in 
some of the samples,  a  low density expression of the monocyte antigen  B52.! 
was observed in a consistent proportion of the cells. In the presence of PHA-CM 
or rIFN~,, a  significant increase in the proportion  of B52.1 ÷ cells was observed 
in most samples. In all experiments, a several-fold increase in the density of the 
B52.1 antigen, as judged by the mean fluorescence intensity, was observed (not 
shown). Thus, after culture with either PHA-CM or rIFNy, a large proportion 
of cells simultaneously expressed the B52.1 monocytic antigen, the B40.8 myeloid 
antigen, and HLA-DR. In the preparations treated with rIFNT, the percentage 
of cells  expressing  FcR  was  also  increased  (Table  I).  The  ability  of the  cell 
preparation  from  donor  7  to  mediate  Ab-CMC  against  P815Y  target  cells 
increased when the cells were cultured in the presence of rIFNy (40.6% specific 
5~Cr-release  at  a  1:1  effector/target  ratio)  as  compared  with  cells cultured  in 
medium alone (22.7% specific 51Cr-release at a 2:1 ratio). 
Effect  of PHA-CM and rlFN7 on  Cultures of Peripheral Blood Myeloid  Cells from 
CML Patients.  Enriched myeloid cells from CML patients were cultured for 5 d 
in  medium supplemented or not with PHA-CM or rIFN7.  Table II and  Fig.  1 
report the results of a typical experiment with the cultured cells from donor C.L. 
On day 0, the majority of the cells expressed myeloid antigens (79.1%) and only 
a small percentage expressed HLA-DR or surface markers of monocytes and T 
cells. After 5 d of culture, however, the expression of the two monocyte antigens 
(B52.1 and B77.1), HLA-DR, FcR, and a-NAE was consistently increased on the 
cells maintained  in  the  presence  of PHA-CM  or rIFNy.  The  increase  of FcR 
expression was observed after 6-8  h  of culture,  whereas the other markers  of 
differentiation were increased beginning days 2 and 3 ofcuhure (data not shown). 
In many cases, the monocyte and HLA-DR antigens were strongly expressed in 
>50% of the cells cultured for 5 d  in the presence of PHA-CM or rIFN-y. The 
expression of the myeloid antigen  recognized by B40.8 did not change signifi- PERUSSIA  ET  AL. 
TABLE  I 
Effect of PHA-CM and rlFN'r on the Expression  of Surface Antigens on 
Normal Bone Marrow Cells 
2063 
HLA-DR  Monocyte  Myeloid 
Exp.  Culture  antigen  antigen  antigen  FcR 
conditions*  (B33.1)*  (B52.1)*  (B40.8)*  (EA7S)° 
1  Medium  7.4  54.5  92.2  ND ! 
PHA-CM  53.2  90.3  91.2  ND 
2  Medium  5.4  47.0  88.7  ND 
PHA-CM  20.1  79.0  91.0  ND 
3  Medium  3.3  1.9  68.4  ND 
PHA-CM  40.8  75.4  49.4  ND 
4  Medium  4.9  74.7  95.5  ND 
PHA-CM  27.0  86.7  72.5  ND 
5  Medium  3.9  50.7  75.8  ND 
PHA-CM  41.9  44.4  57.2  ND 
6  Medium  17.0  72.7  87.6  14.6 
rlFN7  36.2  79.1  80.1  56.5 
7  Medium  4.6  1.5  85.1  30.4 
rIFN~,  32.8  8.3  80.7  84.9 
8  Medium  11.8  11.8  75.3  21.0 
rlFN~,  49.6  35.0  82.7  60.9 
9  Medium  5.4  9.0  78.3  48.9 
rIFN~,  43.1  49.4  67.4  83.7 
I0  Medium  14.9  7.9  70.4  31.4 
rlFN~,  58.7  27.6  57.2  75.4 
11  Medium  4.3  11.8  ND  ND 
rIFN~,  43.5  38.3  ND  ND 
* Bone marrow  cells, prepared as described  in text,  were cultured for 5 d in 
culture medium with or without PHA-CM (50%) or rIFN~, (50 ng/ml). 
Percentage of the cells that express the antigen detected by the monoclonal 
antibody as determined in indirect immunofluorescence  assay (flow cytofluo- 
rometry). 
0 Percentage of cells forming rosettes with EA7S. 
! Not done. 
cantly. A  large proportion of the cells were  induced to express simultaneously 
the  monocyte antigens (B52.1,  B77.1,  and  HLA-DR) and the  myeloid-specific 
antigen, as judged  indirectly by the percentage of cells positive for the various 
markers.  This  observation was  confirmed in a  two-color  immunofluorescence 
assay (data not shown). 
The  cumulative results  with  eight  CML  donors are  reported  in  Table  III. 
Some variability was observed among donors, especially in the ability of the cells 2064  IMMUNE INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
TABLE  II 
Effect of Culture,  PHA-CM, and rlEN'y on the Expression of Various 
Differentiation  Markers on CML Cells 
Marker  Day 0* 
Day 5* 
Medium  PHA-CM  rIFN'r 
HLA-DR antigen (B33.1)  5.4*  4.5  61.3  65.2 
Monocyte antigen (B52.1)  5.7  23.9  61.8  59.0 
Monocyte antigen (B77.1)  ND  0  4.0  52.1  30.0 
Myeloid antigen (B40.8)  79.1  83.0  82.6  80.9 
NK/PMN antigen (B73.1)  2.7  0.8  1.9  0.5 
E receptor (B67.1)  3.9  10.1  15.7  9.8 
Fc receptor (EA7S)  25.01  10.2  33.3  22.4 
c~-NAE  0.0  ~  0.0  17.0  9.0 
* Peripheral blood myeloid cells from CML patient C.L. were analyzed 
on day 0 or after 5-d culture in medium or in the presence of PHA-CM 
(50%) or rlFN3, (50 ng/ml). 
* Percentage of cells that express the antigen detected by the monoclonal 
antibody as determined in indirect immunofluorescence (flow cytofluo- 
rometry). 
0  Not done. 
! Percentage of cells forming rosettes with EA7S. 
Percentage of cells staining for a-NAE. 
to undergo normal differentiation in vitro to mature PMN or to express mono- 
cyte antigens spontaneously.  However, the cells from three donors (A.B., C.S., 
and M.S.) each maintained a  rather constant behavior upon repeated testing. A 
portion of cells from donors C.L. and M.S., cultured in the absence of inducer, 
always expressed B52.1 antigens at low density and, to a  lesser extent, HLA-DR 
antigen.  This  spontaneous  expression  was  never  observed  with  donor  A.B. 
However, as shown in Fig.  1, even in the cases in which monocyte antigens were 
expressed spontaneously (donor C.L.),  PHA-CM and rIFN3, induced a  marked 
increase  in  both  the  percentage  of  positive  cells  and  the  antigenic  density. 
Antibody B67.1 (anti-E receptor) reacted with a small percentage of cells (<10%) 
only when these had been cultured in PHA-CM. 
The  proliferative  capability  of  myeloid  cells  was  assessed  to  exclude  the 
possibility that a small number of monocytes, or monocyte precursors, selectively 
surviving in culture, could overgrow the other myeloid cells. Myeloid cells from 
three  CML  patients  were  tested  for  [3H]TdR  incorporation  during  the  5-d 
culture period (Table IV). The number of cells present at the end of the culture 
was not significantly different from the number of cells originally seeded. The 
proportion of [3H]TdR+ cells, as evaluated by autoradiography, was  16-31% on 
the first day of culture under any of the experimental conditions; it decreased 
on day 2, and only -~ 1-10% of the cells were able to incorporate [SH]TdR under 
any condition at the end of the culture period. We evaluated whether irradiated 
cells (10 Gy) could be induced to differentiate by PHA-CM or rIFN3,. Although 
the results were difficult to interpret due to cell death and low recovery (from 
25  to  40%  after  5-d  cultures),  it  was  observed  that  the  irradiation  dose  used 
completely  prevented  [3H]TdR  incorporation  in  the  cells,  without  affecting 
monocyte differentiation, as evaluated by the induction of both HLA-DR and PERUSS1A  ET  AL.  2065 
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FtGUrE  1.  Effect of PHA-CM or rlFN3, on the expression of surface antigens on CML cells. 
Peripheral blood mononuclear cells from CML patient C.L. were enriched for myeloid cells 
as described in text and cultured for 5 d in culture medium with or without 50% PHA-CM or 
50 ng/ml of rlFN% Cells were then washed, stained by indirect immunofluorescence with the 
indicated monoclonal antibodies, and analyzed with the cytofluorometer. In the histograms, 
the x  axis represents the intensity of fluorescence, and the y axis, the number of cells. The 
broken line represents the histogram obtained when only the second FITC-labeled reagent 
was  added;  the  continuous  line  represents  the  histogram  obtained  when  the  monoclonal 
antibodies have been added. 
monocyte-specific antigens (not shown). 
Effect of Different  Types of lFN on the Expression of Monocyte Differentiation Antigens 
on Myeloid Cells.  Various doses of PHA-CM, rlFN3,, and other IFN types were 
tested on CML cells in culture (Table V and Fig. 2). PHA-CM, purified IFN3, 
(Table V), and rlFN7  (Fig.  2) induced a  dose-dependent increase in  the per- 
centage  of  both  HLA-DR-  and  monocyte  antigen-positive  cells.  The  effect 
induced by rlFN7 was significant at concentrations as low as 1 ng/ml. Purified 
IFN3,  had  a  similar  effect at  approximately  equivalent  antiviral  activity.  No 
significant effect was observed with up to  10 s antiviral U/ml of rlFNA (Table 
V), rlFND, partially purified IFNa, crude and purified IFN~ (results not shown). 
Induction  of Ability  to Mediate Ab-CMC  in  CML  Cells Treated  with  PHA-CM or 
rlFN'y.  The cytotoxic ability of enriched myeloid cell preparations from CML 
patients was usually low or absent. After 5 d of culture with PHA-CM or rlFN3,, 
the cells became highly effective in mediating lysis of IgG antibody-sensitized 
P815Y cells in a 3-h lytic assay (Fig. 3). rlFNA was unable to induce cytotoxicity. 
In the absence of antibodies directed to the target, no spontaneous cytotoxicity 
was observed against various target cell lines (not shown). Induction or strong 
increases in Ab-CMC, after culture in PHA-CM or rlFN3,, was observed in all 2066  IMMUNE  INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
TABLE  Ili 
Effect of PHA-CM on the Differentiation of Cells from Patients with Chronic Myeloproliferative Disorders 
Patients* 
N.S.  J.R.  R.W.  F.M.  J.B.  A.B. (6)  C.L. (9)  M.S. (3)  E.H. 
Age (years)  64  63  56  67  75  76  31  44  68 
Philadelphia  +  +  +  +  +  +  +  -  - 
chrolnosolne 
Myeloid antigen 
(B40.8) 
l)ay 0, medium  ND*  78.1  !  ND  80.2  71.7  77,6 ±  15.9  78.8 ±  10.3  35.6 ±  12.3  40.5 
l)ay 5, medium  5.6  88.6  69,2  82,4  28,4  78,0 ±  10,9  75,8 ±  10.5  48.2 ±  22.9  60.8 
Day 5, PHA-CM  72,9  88.8  73.1  85.4  52.1  76.3 ±  7.4  67.6 +  12.9  36,7 ±  12,0  52,0 
Monocyte antigen 
(B52.1) 
l)~ly 0, medium  ND  3.0  ND  3.1  12.0  3.8 ±  3.0  14.9 ±  13.2  9.7 ±  3.0  9.8 
Day 5, medium  17.9  9. I  49.2  7,8  7.0  14,2 ±  I 1.2  38.9 --. 23.9  32,4 ±  22.2  4.0 
l)~y 5, PHA-CM  44.4  60.2  51.9  57,9  63,3  55.9 ±  18.3  62.2 ±  11.6  58.2 ±  33.4  28.4 
H 1.A-DR (633.1) 
l)ay 0, medium  ND  5.7  ND  4.7  2.7  10.5 ±  5.6  9.0 ±  5.3  8.9 ±  4.4  9.5 
l)ay 5, medium  10.2  4,0  18,2  8.9  36.1  7.4 ±  4.9  22.9 -+ 23.2  23,6 ±  20.2  7.6 
Day 5, PHA-('M  30,0  40.0  44.7  36.7  88,2  39.2 ±  8.2  58.3 +  18.5  60.6 ±  14.1  69.3 
Ab CM(" 
l)ay 0, medium  ND  <0.1 !  <0.1  9.3  0.1  1.5 ±  2.7  5.3 -+ 9.2  ND  ND 
l)ay 5, medium  20.6  8.4  <0.1  9.9  <0.1  11.4 +  15.8  77.6 ±  83.3  ND  ND 
Dny 5, PHA-CM  47.4  125.6  50.4  33.3  9.0  52.7 +_ 57.2  141.3 -+ 97.3  ND  ND 
* Diagnosis  for  all  patients  was CML  in  chronic  phase,  except  for  patient  EH.,  whose  diagnosis  was  myeloid  metaplasia.  The  number  of 
experiments performed on the cells from each patient is given in parentheses. 
* Not done. 
i Percentage  of cells  that  express  the antigen  detected  by  the  monoclonal  antibody,  as  determined  in  indirect  immunofluorescence  (flow 
cytofluorometry).  Data are given as mean --_ SD when at least three experiments were performed on the cells of that donor. 
I LU 45%/107 cells against IgG antibody-sensitized  P815Y target cells in a  3-h SlCr-release assay. 
the  cell  preparations  tested  (Table  III).  The  cultured  cells  from patient  C.L., 
which  were  positive  for  monocyte-specific  antigens  in  the  absence  of inducer, 
were also able to mediate a  low but signficant  level of cytotoxicity  under these 
conditions. 
Analysis of Cultured Myeloid Populations at Different Stages of Differentiation.  The 
preparations  of  myeloid  cells,  separated  from  the  peripheral  blood  of CML 
patients as described above, comprised a mixture of different morphological cell 
types with some variability among donors (e.g.,  in the experiment  described in 
Table  V,  the cell  preparation  was composed of 6%  blasts,  6%  promyelocytes, 
22%  myelocytes,  44%  metamyelocytes,  22%  band and segmented  neutrophils). 
When  the  cells  were  maintained  in  culture  medium  for  5  d,  a  progressive 
differentiation  toward  mature  PMN  was always observed  (3%  myeiocytes,  6% 
metamyelocytes,  91%  band  and  segmented  neutrophils).  However,  myeloid 
maturation was blocked in most cells after 5 d of culture in PHA-CM or rIFN'y: 
nuclei  remained  round  or  kidney-shaped;  the  cells  had  fewer  granules  and  a 
more  irregular  shape  than  the  cells  maintained  in  culture  medium.  A  small 
proportion of large irregular cells had the phagosomes and very strong o~-NAE 
activity characteristic  of macrophages.  All the cells cultured in normal medium 
remained  in  suspension,  whereas  a  variable  proportion  of cells  cultured  with 
PHA-CM or rIFN7 were adherent and spread out on the plastic surface of the 
culture flasks. 
To identify the cells that were able to respond to the differentiation  inducers, 
cell preparations at different stages of differentiation  were purified on the basis PERUSSIA  ET  AL.  2067 
TABLE  IV 
Proliferative Capability of Immature CML Cells in Culture 
Exp.  Treatment* 
Days in culture 
1  2  5 
Number of  [aH]TdR  Number of  [3H]Td R  Number  [~H]TdR 
cells  cells  of cells 
%  %  % 
Medium  6.5*  15.7  g  6.6  13.9  ND I  ND 
PHA-CM  6.5  31.0  6.6  14.7  6.3  9.0 
IFN7  6.5  20.3  5.5  19.7  5.7  7.4 
Medium  4.8  16.7  5.7  13.3  7.5  8.2 
PHA-CM  4.5  26.7  6.3  24.9  9.6  8.7 
IFN7  4.5  16.4  5.4  18.3  7.4  7.9 
Medium  20.0  25.5  18.5  12.5  17.0  10.9 
PHA-CM  18.7  28.5  18.6  13.4  16.0  5.4 
IFN7  19.6  19.3  17.9  12.0  9.5  1.0 
* Immature myeloid cells from three CML patients were kept for 5 d  in culture in RPMI-10% FBS 
medium or in medium containing PHA-CM (50%) or purified IFN% The cells were seeded on day 
0 at 7 ×  10~/ml (exp.  1), 5 ×  105/ml (exp. 2), and 20 x  10~/ml (exp. 3).  Each day of culture, cells 
were pulsed for 1 h with [SH]TdR and centrifuge smears were prepared for autoradiography. After 
3 d, the cells in PHA-CM- and IFN~,-treated cultures were ~50% adherent. 
* Cells X ml  -l ×  10  -~. 
§ Percentage of cells incorporating [SH]TdR. 
! Not done. 
of the  expression  of the  antigen  recognized  by  antibody  B13.4  (anti-PMN, 
monocytes, and mature myeloid cells) and separately cultured. Fig. 4 shows the 
morphology of the cells in a typical experiment and Table V, the analysis of the 
differentiation markers. The B13.4- cell preparations in all donors were com- 
posed mostly of myelocytes (4% blasts, 8% promyelocytes, 76% myelocytes, 12% 
metamyelocytes) (Fig. 4A). The B13.4  + cell preparations were composed almost 
exclusively of metamyelocytes and  band  cells,  with  few  mature  PMN  (45% 
metamyelocytes, 55% band and segmented neutrophils) (Fig. 4D). Upon culture 
in normal medium, both populations continued maturation to PMN, as judged 
morphologically on day 5 and by the expression of the B13.4 antigen on the 
negative cell preparations (not shown). Almost all  B13.4  + cells became mature 
PMN (Fig. 4E), whereas some B13.4- cells remained more immature (mixture 
of metamyelocytes, bands, and mature PMN) (Fig. 4B). Dramatic morphological 
changes occurred in both populations when cells were cultured in the presence 
of PHA-CM (not shown) or rIFN~ (Fig. 4 C and F). In both cases, treatment with 
rIFN~, induced the appearance of cells with monocyte-macrophage  characteristics 
and prevented myeloid differentiation of the cells. 
In the total myeioid cell preparation and in both the separated populations, 
PHA-CM and rIFN%  but not rIFNA,  induced HLA-DR antigen, B52.1  and 
B77.1  monocyte antigens,  FcR,  and  a-NAE  activity (Table  VI).  The modest 
induction by rIFN~' of monocyte antigen on B13.4- cells shown in the experiment 
of Table VI was unusual, insofar as in the other four experiments (see, e.g., Fig. 2068  IMMUNE  INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
TABLE  V 
Effect of Different Types of Inducers on the Expression of Surface 
Antigens on CML Cells 
HLA-DR  Monocyte 
Inducer*  (B33.1)  antigen 
(B52.1) 
None  15.0 (157)*  9.4 (44) 
PHA-CM  50%  75.2 (149)  23.7 (106) 
PHA-CM  10%  60.1  (140)  21.7 (70) 
PHA-CM  2%  23.3 (154)  14.4 (106) 
Purified IFN~,  1,000  U/ml  81.6 (179)  34.3 (71) 
Purified IFN'y  100 U/ml  55.6 (126)  16.5 (86) 
Purified IFN3,  10 U/ml  21.1 (141)  6.1 (68) 
rlFNy  100 ng/ml  85.5 (157)  47.6 (64) 
rIFNA  1,000 U/ml  23.5 (130)  7.6 (53) 
rlFNA  100 U/ml  18.6 (152)  10.0 (38) 
* Peripheral blood myeloid cells from CML patient C.L. were cultured 
for 5 d in the presence of the indicated concentration of inducers. 
* Percentage of cells expressing the antigen detected by the monoclonal 
antibody, as determined by indirect immunofluorescence  (flow  cytofluo- 
rometry). Values in parentheses represent the fluorescence  intensity of 
the positive cells (mean fluorescence  channel). 
2), monocyte antigens were induced by rlFN3, in a  large proportion of B13.4- 
cells. A small proportion of T  cells, as defined by reactivity with antibody B67.1, 
was detected in the cultures treated with the PHA-CM, presumably due to the 
presence of IL-2 in this medium. In the absence of PHA-CM or rlFN3,, only the 
B13.4 + cells, in all donors tested, mediated significant levels of Ab-CMC. In this 
population, PHA-CM or rlFN3, induced only a small increase of cytotoxic ability, 
and,  in some-experiments,  no increase at all.  PHA-CM  or rlFN3,  consistently 
induced an  increase in Ab-CMC on  IgG antibody-sensitized target cells in the 
originally  B13.4-  cell  population.  Again,  rlFNA  was  unable  to  induce  any 
increase in cytotoxicity. 
Induction  of HLA-DR Antigens on Myeloid Cells by PHA-CM or rlFN3,.  Because 
of the complexity of the products of the human Ia genes, some of which probably 
reside at the  HLA-DR locus and others at closely linked loci, six  monoclonal 
antibodies directed against different subpopulations of human Ia antigens were 
used to detect HLA-DR antigens on the cells after culture. As shown in Table 
VII, all six antibodies reacted with a large proportion of myeloid cells from CML 
patients after culture with PHA-CM or rIFN%  None of the antibodies reacted 
with a significant proportion of the cells at the onset of the cultures. The strong 
reactivity of all six anti-Ia monoclonai antibodies tested, which detect different 
subpopulations  of Ia  molecules  (35,  36),  with  the  majority of induced  cells, 
indicated  that  the  various  subpopulations  of  human  Ia  were  induced.  The 
reactivity of the  cells  with antibody Dl-12  (35)  indicated that at  least one of 
these subpopulations is encoded by the DR locus (41) of the HLA region. 80" 
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FIGURE 2.  Effect of different doses of rlFN~' on the expression of surface antigens on CML 
cells. B13.4- peripheral blood myeloid cells from patient M.S. were incubated for 5 d in the 
presence of rlFN7 at the indicated concentrations and then tested by indirect immunofluores- 
cence for the expression of the antigen recognized by different monoclonal antibodies. (0) 
antibody B33.1  (anti-HLA-DR); (I-1) antibody B52.1  (monocyte-specific); and (IB) antibody 
B77.1 (monocyte-specific). 
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FIGURE 3.  Induction of antibody-dependent cytotoxic ability in CML cells by PHA-CM or 
rIFN%  Peripheral blood myeloid cells from patient A.B.  were cultured for  5  days in the 
presence of culture medium, PHA-CM (50%), rIFN7 (50 ng/ml) or rIFNA (10  s antiviral U/ 
ml). The cells were then tested as effectors against antibody-sensitized murine P815Y target 
cells as described. (0) culture medium; (A) PHA-CM; (&) rlFNT; (O) rIFNA. 
Effect of rIFN~,  on  Cultures of Acute Leukemia  Cells.  Cells from six AML and 
from three acute lymphocytic leukemia (ALL) patients were cultured in normal 
medium or in the presence of rIFN% using a protocol similar to that for CML 
cells. The results of the antigenic analysis are reported in Table VIII. In all but Z
 
O
 
Z
 
Z
 
c
~
 
0
 
Z
 
0
 
,
-
]
 
E
 
t
-
~
 
Z
 
Z
 
F
I
G
U
R
E
 
4
.
 
M
i
c
r
o
g
r
a
p
h
s
 
(
X
 
4
4
0
)
 
o
f
 
C
M
L
 
p
e
r
i
p
h
e
r
a
l
 
b
l
o
o
d
 
c
e
l
l
s
 
s
e
p
a
r
a
t
e
d
 
w
i
t
h
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
 
B
1
3
.
4
 
a
n
d
 
i
n
c
u
b
a
t
e
d
 
f
o
r
 
5
 
d
 
i
n
 
c
u
l
t
u
r
e
 
m
e
d
i
u
m
 
w
i
t
h
 
o
r
 
w
i
t
h
o
u
t
 
5
0
 
n
t
~
/
m
l
 
o
f
 
r
l
F
N
%
 
(
A
)
 
B
1
3
.
4
-
 
c
e
l
l
s
,
 
d
a
y
 
0
;
 
(
B
)
 
B
1
3
.
4
-
 
c
e
l
l
s
,
 
c
u
l
t
u
r
e
 
m
e
d
i
u
m
,
 
d
a
y
 
5
;
 
(
C
)
 
B
1
3
.
4
-
 
c
e
l
l
s
,
 
r
l
F
N
%
 
d
a
y
 
5
;
 
(
D
)
 
B
1
3
.
4
"
 
c
e
l
l
s
,
 
d
a
y
 
0
;
 
(
E
)
 
B
1
3
.
4
 
+
 
c
e
l
l
s
,
 
c
u
l
t
u
r
e
 
m
e
d
i
u
m
,
 
d
a
y
 
5
;
 
(
F
)
 
B
1
3
.
4
 
÷
 
c
e
l
l
s
,
 
r
I
F
N
%
 
d
a
y
 
5
.
 PERUSSIA  ET  AL.  2071 
TABLE VI 
Effect of PHA-CM and rlFN~" on Myeloid Cells at Different  Stages of Maturation 
Cell 
prepara-  Treatment  :~  B40.8  B33.1  B52.1  B77.1  B67.1  FcR  a-NAE  Ab-CMC 
tion* 
Total  Medium  84.6!  7.5  5.8  1.4  4.6  9.01  0.0  ~  5.7** 
PHA-CM  86.3  53.7  54.1  45.1  9.9  60.0  17.0  31.0 
rl FN'y  86.2  46.4  23.3  11.4  2.9  68.0  9.0  43.8 
B 13.4  +  Medium  89.8  3.8  6.2  3.6  0.8  38.0  0.0  21.0 
PHA-CM  71.0  49.9  48.1  37.8  4.8  74.0  48.0  34.7 
rlFN'y  71.7  48.9  46.8  27.2  6.0  72.0  38.0  ND  ~ 
rIFNA  84.6  1.5  4.2  1.6  0.4  26.0  1.0  17.2 
BI 3.4-  Medium  85.2  8.8  0.7  1.1  1.7  22.0  0.0  10.8 
PHA-CM  85.4  42.3  49.2  32.5  8.3  61.0  16.0  50.2 
rlFN~,  85.0  34.2  9.4  3.7  7.1  59.0  17.0  39.8 
rtFNA  79.2  6.4  2.9  0.4  0.3  34.0  1.0  7.5 
* Peripheral blood myeloid cells from CML patient A.B. were cultured either unseparated (total) or after separation into BI 3.4  ÷ and 
B 13.4- cells. 
* Cells were cultured for 5 d  in culture medium or in the presence of PHA-CM (50%), rlFN~" (50 ng/ml), or rlFNA (l,O0O  U/ml). 
! Percentage of cells expressing the antigen detected by the indicated antibody, as determined in indirect immunofluorescence (flow 
cytofluorometry) assay. 
I  Percentage of cells forming rosettes with EA7S. 
t Percentage of cells positive for a-NAE. 
** LU 45%/10  ~' cells. 
Not done. 
TABLE  VII 
Reactivity  of Different  Anti-HLA-DR Monoclonal Antibodies  with CML 
Cells Cultured in the Presence of PHA-CM or rlFN'y 
Antibody 
Culture conditions* 
Medium  PHA-CM  rlFN~, 
B33.1  14.0  :~  46.3  45.5 
Dl-12  15.6  66.9  66.4 
Q2/70  18.9  68.8  72.3 
Q2/80  5.6  58.9  61.7 
Q5/6  11.2  67.2  68.2 
Q5/13  17.9  75.1  82.7 
* Myeloid cells (BI 3.4-) from the peripheral  blood of CML patient M.S. 
were incubated for 5 d in culture  medium or in the presence of PHA- 
CM (50%) or rIFN~, (50 ng/ml). 
* Percentage of cells expressing the antigen detected by the monoclonal 
antibody, as determined  in indirect immunofluorescence (flow cytofluo- 
rometry). 
one of the AML preparations,  both the intensity of antigen expression and  the 
percentage  of cells  positive  with  anti-HLA-DR  antibodies  increased.  In  some 
cases,  a  moderate  increase  in  the  proportion  of the  B52.1  monocyte antigen- 
positive cells, and,  in most cases of AML, an increased expression of FcR, were 
also  observed.  No  significant  increases  in  the  expression  of HLA-DR,  B52.1 
antigen,  FcR,  or  a-NAE  activity  were  observed  with  the  cells  from  the  three 
ALL cases. Fig.  5  depicts the flow cytofluorometry analysis of the expression of 
HLA-DR  and  B52.1  antigens  in  two  of the  AML  cases.  The  M2  leukemia 
represents an example of a  case in which  HLA-DR antigens were expressed on 2072  IMMUNE  INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
TABLE  VIII 
Effect of rlFN3, on the Expression of Differentiation Markers in Cells  from Patients 
with Acute Leukemia 
Diagnosis 
H LA-DR (B33.1)*  Monocyte Ag (B52. I)*  FcR (EA7S)  t  a-NAE  ! 
Day 5  Day 5  Day 5  Day 5 
Day O  Day 0  Day 0  Day 0 
Medium  rlFN3'  Medium  rIFN~/  Medium  rlFN~,  Medium  rlFN'y 
AML(MI)  60.9  63.7  68.3  2.0  4.7  17.7  0.0  28.0  65.0  8.6  14.0  73.0 
AML (MI)  36.9  45.5  78.8  0.6  3.6  9.6  0.0  0.0  9.2  ND  I  1.0  8.0 
AML (M2)  25.9  62.2  92.0  2.3  6.4  16.0  14,0  6.0  10.5  ND  6.0  76.0 
AML (M3)  9.2  2.4  53.2  1.6  0.6  22.8  2.0  0.0  37.5  7.5  0.0  83.0 
AML (M4)  70.3  68.5  85.3  8.2  17.8  16.2  7.0  6.9  54.9  20.0  5.0  39.0 
AML (M4)  56.8  86.6  68.8  23.9  15.6  28.2  32.0  22.6  42.2  95.0  18.5  48.0 
ALL  90.1  86.8  95.0  5.1  ND  ND  1.0  20.6  35.9  0.0  0.0  0.0 
(pre-B) 
ALL(B)  84,3  41.0  25.3  3.6  ND  ND  1.0  1.9  3.0  0.0  0.0  0.0 
ALL (T)  0,4  4.1  4.3  0.5  2,9  3.2  0.0  1.7  2.0  0.0  0,0  0.0 
*  Peripheral blood cells from the patients were analyzed  at day 0 or after 5-d incubation in culture medium with or without rIFN~, 
(50  ng/ml). Data  are  percentages  of cells expressing  the antigen detected  by  the  monoclonal  antibody,  as analyzed  in indirect 
immunofluorescence  (flow cytofluorometry). 
t Percentage  of cells forming rosettes  with EATS. 
! Percentage  of cells staining for a-NAE. 
I Not done. 
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FIGURE 5.  Effect of rIFN~, on the expression of HLA-DR and monocyte surface antigens on 
AMLcells. Peripheral blood cells from two patients were maintained in culture medium or in 
the presence of 50 ng/ml of rIFN~" for 5 d and then analyzed by indirect immunofluorescence 
with antibodies B33.1  and B52.1.  In  the histograms, the x  axis represents the intensity of 
fluorescence, and the y axis, the number of cells. The broken line represents the histogram 
obtained when only the second  FITC-labeled  reagent was added,  and the continuous line 
represents the histogram obtained when the monoclonal antibodies were added. 
a  large proportion of cells at the beginning of the culture, but in which rIFN~, 
induced a strong increase in both the density of the antigen and the number of 
positive cells.  The promyelocyte  leukemia  (M3) represents a  case of HLA-DR- 
negative,  B52.1-negative  cells  that  can  be  induced  by  rIFN~,  to express  both 
HLA-DR  and  B52.1  antigens,  similar  to  the  observations  made  in  human 
promyelocytic cell lines (9), normal bone marrow cells, and CML cells. 
Inhibition of Induction of CML Cell Differentiation by Anti-IFN Serum.  The induc- 
tion of HLA-DR  ÷ cells by either rIFN'y or PHA-CM in immature (B13.4-) cells 
from  CML  patients  was  blocked  when  rabbit  anti-human  IFN~  was  present PERUSSIA  ET  AL.  2073 
TABLE  IX 
Effect of Anti-IFN3" on PHA-CM and rlFN'y-dependent Induction of CML Differentiation 
HLA-DR*  Monocyte  Myeloid  FcR! 
antigen  antigen  Culture conditions*  (B33.1)  (B52.1)  (B40.8)  (EA7S) 
Medium  7.0 (138)  9.5 (64)  77.2 (195)  38.9 
PHA-CM  40.4 (128)  51.4 (115)  81.5 (195)  77.3 
PHA-CM + NRS  37.5 (109)  58.2 (117)  70.6 (192)  78.0 
PHA-CM + rabbit anti-IFN'r  12.2 (152)  44.9 (87)  80.3 (191)  46.4 
rIFN3" + NRS  21.6 (132)  22.7 (108)  71.9 (193)  84.2 
rI FN~/+ rabbit anti-IFN'r  12.0 (137)  9.4 (86)  77.8 (193)  13.5 
* B13.4- myeloid cells from patient A.B. were cultured for 5 d (2 x  l0  B  cells/ml) in medium with or 
without PHA-CM (50%) or rIFN3, (50 ng/ml) in the presence  or absence of rabbit anti-human 
IFN3, (1:40 dilution, corresponding to 250 neutralizing  U/ml) or normal rabbit serum (NRS) (1:40 
dilution). 
* Percentage of cells expressing  the antigen detected by the  indicated monoclonal antibody, as 
determined in indirect immunofluorescence  (flow cytofluorometry). The mean fluorescence inten- 
sity, in arbitrary units ranging from 1 to 200, is given in parentheses. 
Percentage of cells forming rosettes with EA7S. 
during  the  5-d culture period (Table IX). The percentage of cells induced to 
express monocyte antigen  B52.1  by rIFN7 or by PHA-CM was reduced, espe- 
cially when rIFN7 was the inducer. In both cases, the density of the antigen, as 
judged by the intensity of fluorescence, was also much lower than that observed 
in the respective induced cells cultured in the presence of normal rabbit serum 
(NRS).  No significant  change  in  the proportion  of B40.8 ÷ cells was observed. 
Noninduced  cells and  cells induced by rIFN3'  or PHA-CM in the presence of 
rabbit anti-IFN7 were nonadherent;  by contrast, a  large proportion of the cells 
in rIFNy- or PHA-CM-induced cultures in the presence or absence of NRS were 
adherent. 
Discussion 
The block in differentiation of leukemia cells or cell lines derived from them 
often can  be overcome in  vitro by the  use of synthetic or naturally  occurring 
inducers. Though the characteristics of the process of differentiation delineated 
in these systems are thought to approximate those of normal differentiation (42, 
43), they might only represent an aberration linked to mutations in the cell line, 
as  a  function  of their  leukemic  origin  or  of a  long  in  vitro  culture  history. 
Nevertheless, established cell lines provide an unlimited number of homogeneous 
cells and,  as  a  consequence,  the  possibility of defining  optimal  experimental 
conditions  for  the  induction  of differentiation,  and  of identifying  the  most 
reliable markers for an analysis of cell maturation.  By monitoring those surface 
markers,  surface receptors, enzymatic activities, and cellular functions shown in 
our previous studies to be the most relevant for myeloid differentiation (9,  32, 
34, 44), we now show that both PHA-CM and IFN3, induce normal or leukemic 
immature human myeloid cells to differentiate along the monocytic pathway. 
Chiao  et al.  (10) reported  that  PHA-CM  induces  maturation  of AML cells. 
Using rlFN-r, we were able to induce at least some of the markers of monocytic 
differentiation  in  six  cases  of AML  analyzed;  in  one  case  of promyelocytic 2074  IMMUNE  INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
leukemia (M3), the induced pattern of differentiation of surface markers and o~- 
NAE activity was indistinguishable from that observed with promyelocytic cell 
lines (9). We were able to induce analogous monocytic differentiation of myeloid 
cells  from  normal  bone  marrows  and  CML  patients,  using this experimental 
protocol. CML peripheral blood contains a  large number of immature myeloid 
cells  that,  despite  their  clonal  origin  and  chromosomal  anomalies,  undergo 
maturation  to terminal  cells (monocytes and  PMN)  both in vivo and in vitro. 
Immature myeloid cells cultured in the presence of PHA-CM or IFN3, acquired 
characteristics of monocyte-macrophages, as evidenced by (a) the morphological 
resemblance of most cells to monocyte-macrophages without myeloid maturation 
and segmentation of the nuclei; (b) the inductioti of several surface and enzymatic 
markers of monocytes in the majority of the cells; (c) development of phagocytic 
ability for EA7S in most of the cells (not shown); and (d) the ability to mediate 
high levels of Ab-CMC.  We have shown previously (9) that a  subpopulation of 
HL-60 cells, induced to undergo maturation and incapable of further prolifera- 
tion,  simultaneously  expresses  all  of these  differentiation  markers;  a  second 
subpopulation, unresponsive to the differentiation inducer, maintains prolifera- 
tive ability and expresses none of the differentiation markers. The expression of 
all the differentiation markers by the majority of cells in the present experiments 
suggests that at least a portion of the cells simultaneously expresses the markers 
characteristic of normal monocytes. In a few initial experiments, we observed T 
cell growth  induced by  PHA-CM  containing large  quantities  of IL  2;  careful 
elimination of contaminant T  cells, as confirmed by analysis for T  cell markers 
both before and after culture, avoided this potentially confounding factor. 
IFN3' induces high levels of Ia antigen on the Ia-negative immature myeloid 
cells during induction of these cells along the monocytic pathway. The earliest 
observable effect of IFNy is the induction of FcR for monomeric human IgG1 
within 8-12  h  of incubation (26)  followed  1-2 d  later by the expression of Ia 
antigens and, finally, the other markers. The reaction of the antibody with the 
differentiated  cells  is  not  due  to  FcR  binding,  because:  (a)  the  expression  of 
differentiating antigen is not detected during the first  24-48  h  of incubation, 
when FcR are already fully expressed; (b) F(ab')2 fragments of both B33.1  and 
goat anti-mouse Ig antibody were used; (c) the antimonocyte antibodies were all 
IgM  that  do  not  bind  to  the  FcR  induced by  IFN3,;  (d)  the  presence of 5% 
human serum used during cell incubation and washing competitively blocked the 
FcR; and (e) control irrelevant monoclonal antibodies did not bind to the cells. 
Analogous to our findings with promyelocytic lines (9),  the majority of the 
cells in the preparations from normal bone marrows and the peripheral blood of 
CML  patients  expressed  the  myeloid antigen  recognized  by  antibody  B40.8. 
Induction of monocyte markers was not accompanied by significant reduction in 
the expression of this antigen.  One possible interpretation  of these findings is 
that promyelocytes have already acquired antigenic, enzymatic, and morpholog- 
ical properties of the granulocyte lineage toward which they are differentiating, 
but are not yet irreversibly committed to that lineage and thus can be redirected 
toward the monocytic lineage (45). Cells with intermediate enzymatic character- 
istics of granuiocytes and monocytes can be identified in normal bone marrow 
(46), and cells from AML (M4) patients often display surface markers of both PERUSSIA  ET  AL..  2075 
granulocytes and monocytes (45, and our unpublished observation). Our results 
with CML cells suggest that metamyelocytes and band neutrophils can still  be 
induced to coordinately express a series of differentiation markers characteristic 
of normal  monocytes, although  the  morphological,  antigenic,  and  enzymatic 
properties identify the induced cells more as intermediate myelomonocytic cells 
than as fully differentiated monocytes (47). 
The analogy between the induction by PHA-CM and IFN3, of differentiation 
markers on myeloid cell lines and on the culture of normal or leukemic myeloid 
cells  and  the  persistence  in  the  differentiated  monocytoid  cells  of  myeloid 
antigens  never expressed  on  normal  monocytes, suggests  that  the  cells  with 
monocyte characteristics are derived from the myeloid cells. The possibility that 
monocytes or immature monocytes selectively survive in the presence of PHA- 
CM or IFN3, is excluded by the cell purification procedures used, which elimi- 
nated all monocytes and a-NAE-positive cells, and by the limited extent of cell 
death in the cultures.  However, a  very small number of monocyte precursors 
could escape the cell separation procedures and overgrow the myeloid cells in 
the presence of PHA-CM  or  IFN3,.  A  series of experimental data makes this 
possibility unlikely. Although crude PHA-CM contains CSF, no significant colony 
formation in methylcellulose is induced by the presence of rIFN3, using as target 
cells either normal bone marrow cells or peripheral blood  CML  cells.  In  the 
cultures of CML cells, the number of cells able to incorporate [3H]TdR rapidly 
decreased after the  first  1  or  2  d  of culture,  indicating that  the number of 
possibly replicating cells was too low to allow the overgrowing of the culture by 
a small number of monocyte precursors. Finally, experiments of 3' irradiation of 
the cells, although troubled by a  decreased cell viability, showed induction of 
monocyte differentiation in CML cells in the absence of cell replication. 
Mature  PMN  from  normal  peripheral  blood  survive only  1  or  2  d  in  our 
culture conditions and PHA-CM or rIFN3" were unable to induce them to express 
HLA-DR or monocyte antigens.  However, we have reported (26) that even a 
brief incubation of mature PMN  with IFN3" results in the expression on these 
cells of an FcR for human monomeric IgG 1, with affinity and specificity analo- 
gous to that expressed by monocytes. As previously observed with HL-60 and 
other promyelocytic cell lines (9), induction of FcR is necessary but not sufficient 
to confer cytotoxic ability to  the cells.  Apparently, the ability to  mediate Ab- 
CMC requires more complete maturation of the cells than does expression of 
the other monocytic markers.  The ability to  lyse  IgG-sensitized  P815Y  cells, 
however, is  shared by monocytes, PMN  and  LGL  (27).  The observation that 
myeloid maturation of CML can occur spontaneously might explain the occa- 
sional  generation  of antibody-dependent  cytotoxic ability  in  the  absence  of 
inducers seen in preparations of more mature myeloid cells. In some experiments, 
PHA-CM or IFN3" decreased this activity, probably by blocking myeloid matura- 
tion  without  inducing  complete monocytic differentiation.  It  is  unlikely that 
PHA-CM and IFN3" act by enhancing the cytotoxic ability of a few contaminant 
LGL, rather than by inducing this ability in myeloid cells, because: (a) IFN are 
potent activators of the spontaneous cytotoxicity of LGL, but are almost com- 
pletely  ineffective  in  enhancing  Ab-CMC  (15,  17,  48);  (b)  no  spontaneous 
cytotoxic activity against target cells susceptible to lysis mediated by LGL was 2076  IMMUNE  INTERFERON-INDUCED  MONOCYTIC  DIFFERENTIATION 
ever mediated by the cell preparations in culture; (c) LGL were removed from 
our cell preparations by using antibody B73.1, directed against an antigen present 
on all  LGL, and antibody B67.1,  which reacts with the majority of them (30, 
49); and (d) after culture in the presence of IFN3,,  no significant number of 
B73.1 + or B67.1 + cells were observed. 
We observed that purified or recombinant IFN3, closely mimics the effect of 
PHA-CM in inducing monocytic differentiation in myeloid cells. PHA-CM con- 
tains,  in addition to IFN3, (12),  various other lymphokines, including CSF.  In 
addition to their ability to induce differentiation by affecting proliferation, CSF 
can also act by influencing RNA and protein synthesis in  mature postmitotic 
neutrophilic granulocytes (50, 51). Olsson et al. (52) reported that concanavalin 
A-induced CM contained two molecular species of differentiation-inducing fac- 
tors: one is a 25,000 D species that coelutes with the colony-stimulating activity, 
and the other, a  40,000  D species not associated with this activity. The factor 
present in our PHA-CM that induces differentiation in HL-60 cells is destroyed 
at pH 2.0 or at 56°C, has a molecular weight of 40,000-50,000,  elutes, by gel 
filtration,  in  the  same  fractions  as  IFN7  activity,  and  is  inactivated  by  an 
antiserum against IFN3,. 2 We were able to inhibit the rIFN3,-induced monocytic 
differentiation of immature  myeloid cells by adding anti-IFN7  serum at  the 
beginning of the culture. When the same antiserum, in which no activity against 
CSF was demonstrable, was added to PHA-CM-induced cultures, HLA-DR and 
FcR expression was blocked and a much reduced proportion of the induced cells 
expressed low levels of the B52.1  antigen. Our data, therefore, show that IFN-¢ 
is the predominant type of differentiation-inducing factor contained in the PHA- 
CM.  The  inability  of the  rIFN~,  preparation  to  induce  colony formation  in 
normal bone marrow or peripheral blood CML cells suggests that CSF is not 
primarily involved in the differentiation induced by IFN3,.  However, the possi- 
bility that the differentiation-inducing ability of PHA-CM remaining after treat- 
ment with anti-IFN3, serum resides in CSF requires further investigation. 
The effect of IFN~, on the differentiation of myeloid cells to HLA-DR-positive 
mature "monocytoid" cells that we describe has biological relevance for both the 
adaptive and nonadaptive arms of the immune system and for the regulation of 
hematopoiesis. Monocyte-macrophages can produce and secrete a series of sub- 
stances with regulatory effects on both the hematopoietic and immune systems. 
Ia-positive macrophages and precursor cells play a  complex regulatory role in 
the control of proliferation and maturation of both normal and leukemic myeloid 
cells (53). Moreover, the Ia-positive cells might be able to function as accessory 
or antigen-presenting cells.  IFNa,  the type of IFN commonly used in  clinical 
trials, not only lacks the ability to mediate most of these regulatory effects, but 
also exerts an inhibitory and antiproliferative effect on myelopoiesis (18).  The 
specific regulatory functions of IFN3, on myelomonocytic differentiation should 
be kept in mind when interpreting observations made during future therapeutic 
trials of rIFNy. 
Summary 
Conditioned medium from phytohemagglutinin-stimulated human leukocytes 
contains a  factor  that  can  induce  promyelocytic cell  lines  and  certain  acute PERUSSIA  ET  AL.  2077 
myelogenous leukemia cells to differentiate along the monocytic pathway. In this 
report, we show that immature myeloid cells from normal bone marrow or the 
peripheral blood of patients with chronic myelogenous leukemia can be induced 
to differentiate to monocyte-like cells by immune 7 interferon (IFN~,). We have 
identified  IFN~,  as  the  predominant  differentiation factor  contained  in  the 
conditioned medium. Purified or recombinant IFN~,,  but not various prepara- 
tions of IFNa or 3,  can induce monocytic differentiation in myeloid cells.  In 
cultures  containing  conditioned  medium,  the  cells  fail  to  continue  myeloid 
maturation, and are induced to express monocyte markers and functions, such 
as monocyte-specific surface antigens, HLA-DR antigens, Fc receptors for mon- 
omeric immunoglobulins, nonspecific esterase, and the ability to mediate anti- 
body-dependent, cell-mediated cytotoxicity. Even  myeloid cells  as  mature  as 
metamyelocytes or band cells can be induced by IFN~,  to undergo monocyte 
differentiation, but monocyte-specific or HLA-DR antigens are not induced in 
mature neutrophils. These findings reveal a previously unknown, specific func- 
tion  of human  IFN'y and  offer new  insights to  the  regulation of monocyte 
recruitment and differentiation during a virus infection or immune response. 
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